UMass Chan Affiliations
Department of PediatricsDocument Type
Journal ArticlePublication Date
2010-05-01Keywords
Administration, InhalationAnti-Bacterial Agents
use
Aztreonam
Cystic Fibrosis
Drug Discovery
Humans
Lysine
Pseudomonas Infections
Pseudomonas aeruginosa
Treatment Outcome
Allergy and Immunology
Pediatrics
Respiratory Tract Diseases
Metadata
Show full item recordAbstract
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.Source
Nat Rev Drug Discov. 2010 May;9(5):357-8. Link to article on publisher's siteDOI
10.1038/nrd3170Permanent Link to this Item
http://hdl.handle.net/20.500.14038/43832PubMed ID
20431562Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1038/nrd3170